Guangdong Wantai Kechuang Pharmaceutical

Guangdong Wantai Kechuang Pharmaceutical is a clinical-stage biopharmaceutical company based in Guangzhou, China, dedicated to the discovery and development of innovative therapies for metabolic and chronic diseases. The company's research focus centers on high-potential therapeutic areas such as obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). Its lead programs include WT-1106, a long-acting triple agonist targeting GLP-1, GIP, and glucagon receptors, and WT-01, a selective thyroid hormone receptor beta (THR-beta) agonist. By leveraging its internal R&D capabilities in small molecule and peptide drug design, Wantai Kechuang aims to provide next-generation solutions for the global metabolic health crisis. The firm operates primarily out of the Nansha District high-tech hub, positioning itself as a key player in the regional biotech ecosystem.